Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Recent & Breaking News (NDAQ:SCYX)

SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update

GlobeNewswire July 14, 2022

SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

GlobeNewswire June 23, 2022

SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

GlobeNewswire June 8, 2022

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 3, 2022

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

GlobeNewswire May 20, 2022

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

GlobeNewswire May 10, 2022

SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

GlobeNewswire May 5, 2022

SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

GlobeNewswire May 4, 2022

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp's Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

GlobeNewswire April 27, 2022

SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

GlobeNewswire April 26, 2022

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

GlobeNewswire April 22, 2022

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

GlobeNewswire April 22, 2022

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

GlobeNewswire April 21, 2022

SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal

GlobeNewswire April 20, 2022

SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives

GlobeNewswire April 19, 2022

SCYNEXIS to Participate in Upcoming April Women's Health Medical Conferences

GlobeNewswire April 4, 2022

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 29, 2022

SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

GlobeNewswire March 24, 2022

SCYNEXIS Named to Fast Company's 2022 Top 50 List of the World's Most Innovative Companies

GlobeNewswire March 8, 2022